Great news for Pfizer?-To The Moon - Tiger Brokers Online Investing Community - To The Moon

7
3
Favorite

YeeMeng
2021-09-21

Great news for Pfizer?

J&J Says Covid-19 Vaccine Booster Two Months After First Shot Increases Protection

Trial participants in the U.S. who received a second dose eight weeks after the first had 94% protec

J&J Says Covid-19 Vaccine Booster Two Months After First Shot Increases Protection

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

7

Report

Comment（3）

Top
Latest

iamme
·2021-09-21
ya
Reply
Like
Report
JohnLeeToday
·2021-09-21
MaybE
Reply
Like
Report
bostonxsgp
·2021-09-21
ok
Reply
Like
Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":869008484,"tweetId":"869008484","gmtCreate":1632223362448,"gmtModify":1676530728006,"author":{"id":3582597737343890,"idStr":"3582597737343890","authorId":3582597737343890,"authorIdStr":"3582597737343890","name":"YeeMeng","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":12,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Great news for Pfizer?</p></body></html>","htmlText":"<html><head></head><body><p>Great news for Pfizer?</p></body></html>","text":"Great news for Pfizer?","highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/869008484","repostId":1157787805,"repostType":4,"repost":{"id":"1157787805","pubTimestamp":1632222985,"share":"https://www.laohu8.com/m/news/1157787805?lang=&edition=full","pubTime":"2021-09-21 19:16","market":"us","language":"en","title":"J&J Says Covid-19 Vaccine Booster Two Months After First Shot Increases Protection","url":"https://stock-news.laohu8.com/highlight/detail?id=1157787805","media":"The Wall Street Journal","summary":"Trial participants in the U.S. who received a second dose eight weeks after the first had 94% protec","content":"<blockquote>\n <b>Trial participants in the U.S. who received a second dose eight weeks after the first had 94% protection against the illness.</b>\n</blockquote>\n<p>Johnson &amp; JohnsonJNJ-0.57%said a booster dose of its Covid-19 vaccine administered two months after the first shot increased protection against symptomatic illness in trial participants, as federal regulators evaluate data for the country’s strategy for rolling out boosters.</p>\n<p>Data released Tuesday from a late-stage clinical trial showed that study participants in 10 countries including the U.S. who received a second dose of the company’s vaccine two months after the first had 75% protection against symptomatic Covid-19. Participants in the U.S. had 94% protection against the illness. J&amp;J didn’t explain the reason for the difference in efficacy rates.</p>\n<p>A double dose of the vaccine provided participants with 100% protection against severe or critical Covid-19 at least two weeks after the second shot, J&amp;J said.</p>\n<p>The company earlier this year said a large clinical trial showed thata single dose of its vaccine was 66% effectiveat protecting people from moderate to severe Covid-19.</p>\n<p>“We now have generated evidence that a booster shot further increases protection against Covid-19 and is expected to extend the duration of protection significantly,” said Paul Stoffels, chief scientific officer at J&amp;J. The company said it has shared available data with the Food and Drug Administration.</p>\n<p>The late-stage study tested a two-dose regimen of the vaccine in about 32,000 people aged 18 and over in the U.S., Belgium, Brazil, Colombia, France, Germany, the Philippines, South Africa, Spain and the U.K., J&amp;J said. The company said about half of participants received the placebo but didn’t say how many participants were in the U.S.</p>\n<p>J&amp;J said Tuesday that an extra shot given two months after the firstboosted antibody levels four to six times higherthan observed after the single shot. It said a booster administered six months after the first shot initially increased antibody levels ninefold and continued to climb to 12-fold higher four weeks after the second shot. J&amp;J released some of thesix-month boosting datain August.</p>\n<p>Neither that data nor the results released Tuesday have been peer reviewed or published in a scientific journal.</p>\n<p>“The data are supportive of giving a second shot of the J&amp;J vaccine, anywhere from two months onwards,” said Dan Barouch, an immunologist at Beth Israel Deaconess Medical Center in Boston who helped develop J&amp;J’s vaccine. “The longer you wait, the better the boost will likely be.”</p>\n<p>He said some countries might choose to offer boosters, while others might stick with a single shot. “Different people or different countries might actually make different choices based on what their desires or needs are,” Dr. Barouch said.</p>\n<p>J&amp;J also highlighted data it said showed its single-shot vaccine offered durable protectioneven as the Delta variant spreads.</p>\n<p>In a study of about 390,000 people in the U.S. who received the J&amp;J vaccine compared with 1.52 million similar unvaccinated people from March to late July 2021,the single-dose vaccine was 79% effectiveagainst infections and 81% effective against hospitalizations related to Covid-19.</p>\n<p>The Biden administration is hoping to begin at least part of its boosting strategy this week. It is waiting for the FDA to authorize additional doses of the vaccine fromPfizerInc.andBioNTech SEfor people who are 65 years old and over or at high risk of developing severe Covid-19. A Centers for Disease Control and Prevention advisory panel is set to discuss the Pfizer boosting strategy on Wednesday and Thursday.</p>\n<p>Plans to offer boosters more widely were scaled back as federal health officials and medical expertsremain divided over the need for boostersand regulators have asked for more time to review data from J&amp;J andModernaInc.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J Says Covid-19 Vaccine Booster Two Months After First Shot Increases Protection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J Says Covid-19 Vaccine Booster Two Months After First Shot Increases Protection\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-21 19:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/j-j-says-covid-19-vaccine-booster-two-months-after-first-shot-increases-protection-11632220201?mod=hp_lead_pos3><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Trial participants in the U.S. who received a second dose eight weeks after the first had 94% protection against the illness.\n\nJohnson & JohnsonJNJ-0.57%said a booster dose of its Covid-19 vaccine ...</p>\n\n<a href=\"https://www.wsj.com/articles/j-j-says-covid-19-vaccine-booster-two-months-after-first-shot-increases-protection-11632220201?mod=hp_lead_pos3\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.wsj.com/articles/j-j-says-covid-19-vaccine-booster-two-months-after-first-shot-increases-protection-11632220201?mod=hp_lead_pos3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157787805","content_text":"Trial participants in the U.S. who received a second dose eight weeks after the first had 94% protection against the illness.\n\nJohnson & JohnsonJNJ-0.57%said a booster dose of its Covid-19 vaccine administered two months after the first shot increased protection against symptomatic illness in trial participants, as federal regulators evaluate data for the country’s strategy for rolling out boosters.\nData released Tuesday from a late-stage clinical trial showed that study participants in 10 countries including the U.S. who received a second dose of the company’s vaccine two months after the first had 75% protection against symptomatic Covid-19. Participants in the U.S. had 94% protection against the illness. J&J didn’t explain the reason for the difference in efficacy rates.\nA double dose of the vaccine provided participants with 100% protection against severe or critical Covid-19 at least two weeks after the second shot, J&J said.\nThe company earlier this year said a large clinical trial showed thata single dose of its vaccine was 66% effectiveat protecting people from moderate to severe Covid-19.\n“We now have generated evidence that a booster shot further increases protection against Covid-19 and is expected to extend the duration of protection significantly,” said Paul Stoffels, chief scientific officer at J&J. The company said it has shared available data with the Food and Drug Administration.\nThe late-stage study tested a two-dose regimen of the vaccine in about 32,000 people aged 18 and over in the U.S., Belgium, Brazil, Colombia, France, Germany, the Philippines, South Africa, Spain and the U.K., J&J said. The company said about half of participants received the placebo but didn’t say how many participants were in the U.S.\nJ&J said Tuesday that an extra shot given two months after the firstboosted antibody levels four to six times higherthan observed after the single shot. It said a booster administered six months after the first shot initially increased antibody levels ninefold and continued to climb to 12-fold higher four weeks after the second shot. J&J released some of thesix-month boosting datain August.\nNeither that data nor the results released Tuesday have been peer reviewed or published in a scientific journal.\n“The data are supportive of giving a second shot of the J&J vaccine, anywhere from two months onwards,” said Dan Barouch, an immunologist at Beth Israel Deaconess Medical Center in Boston who helped develop J&J’s vaccine. “The longer you wait, the better the boost will likely be.”\nHe said some countries might choose to offer boosters, while others might stick with a single shot. “Different people or different countries might actually make different choices based on what their desires or needs are,” Dr. Barouch said.\nJ&J also highlighted data it said showed its single-shot vaccine offered durable protectioneven as the Delta variant spreads.\nIn a study of about 390,000 people in the U.S. who received the J&J vaccine compared with 1.52 million similar unvaccinated people from March to late July 2021,the single-dose vaccine was 79% effectiveagainst infections and 81% effective against hospitalizations related to Covid-19.\nThe Biden administration is hoping to begin at least part of its boosting strategy this week. It is waiting for the FDA to authorize additional doses of the vaccine fromPfizerInc.andBioNTech SEfor people who are 65 years old and over or at high risk of developing severe Covid-19. A Centers for Disease Control and Prevention advisory panel is set to discuss the Pfizer boosting strategy on Wednesday and Thursday.\nPlans to offer boosters more widely were scaled back as federal health officials and medical expertsremain divided over the need for boostersand regulators have asked for more time to review data from J&J andModernaInc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":494,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":19,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":5945703,"commentId":"5945703","gmtCreate":1632223431001,"gmtModify":1663234212344,"authorId":3581890649918848,"author":{"id":3581890649918848,"idStr":"3581890649918848","authorId":3581890649918848,"name":"iamme","avatar":"https://static.tigerbbs.com/fe38c555d52f708161a2da155b67f28b","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":869008484,"objectIdStr":"869008484","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"<u>ya</u>","text":"<u>ya</u>","html":"<u>ya</u>","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0},{"id":5945702,"commentId":"5945702","gmtCreate":1632223418341,"gmtModify":1663234211132,"authorId":3584930099421547,"author":{"id":3584930099421547,"idStr":"3584930099421547","authorId":3584930099421547,"name":"JohnLeeToday","avatar":"https://static.tigerbbs.com/f50ae8cdbdb7309ac4d36b63ed8e0734","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":869008484,"objectIdStr":"869008484","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"MaybE","text":"MaybE","html":"MaybE","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0},{"id":5945754,"commentId":"5945754","gmtCreate":1632223909042,"gmtModify":1634790271733,"authorId":3584157491931754,"author":{"id":3584157491931754,"idStr":"3584157491931754","authorId":3584157491931754,"name":"bostonxsgp","avatar":"https://static.tigerbbs.com/55d82efabeabddb18cc2d6ca7a71a36f","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.85%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":869008484,"objectIdStr":"869008484","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"ok","text":"ok","html":"ok","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}